What does REVISION IMPLANT do?

REVISION IMPLANT is a research organisation in Oud-Heverlee. Public Limited, started on 23 December 2019, 1 establishment.

What is the address of REVISION IMPLANT?

The registered office of REVISION IMPLANT is located at Blandenstraat 31, 3053 Oud-Heverlee.

Is REVISION IMPLANT still active?

Yes. According to the CBE (29 October 2026) REVISION IMPLANT is active, legal situation “Normale toestand”, started on 23 December 2019.

Is REVISION IMPLANT registered on Peppol?

Yes, REVISION IMPLANT is registered on the Peppol network with ID 0208:0740519675.

What is the enterprise number of REVISION IMPLANT?

The enterprise number of REVISION IMPLANT is BE0740519675.

When was REVISION IMPLANT founded?

REVISION IMPLANT was founded on 23 December 2019.

Is REVISION IMPLANT a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 23 December 2019; 5 annual accounts filed, latest fiscal year 2025; 6 directors known from the annual account.

How much profit did REVISION IMPLANT make in 2025?

REVISION IMPLANT recorded a loss after taxes of € 36,000 in financial year 2025.

What is the revenue of REVISION IMPLANT?

As a small company, REVISION IMPLANT is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 433,649.

How much does an employee at REVISION IMPLANT earn?

The average wage cost per full-time employee at REVISION IMPLANT was € 58,100 in 2024: staff costs of € 307,853 for 5.3 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

REVISION IMPLANT (Public Limited) - Oud-Heverlee

Q: Who are the directors of REVISION IMPLANT?

According to the 2025 annual accounts, the directors of REVISION IMPLANT are: Jasmine Peeters, Maarten Schelles, Johan Van de Bossche, Dagda Ventures, Frederik Ceyssens, Ruben Verhoeven.

Dossier REVISION IMPLANT, printed on 29 October 2026 from databakkes.be/en/0740519675/revision-implant. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.

Financials

Financial year 2025

REVISION IMPLANT from Oud-Heverlee, company number BE0740519675, closed financial year 2025 with a result of € -36,000 after tax. For that financial year REVISION IMPLANT recorded a gross margin of € 433,649 and equity of € 387,038. Compared with financial year 2024, the result moved from € -293,396 to € -36,000. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 17, 2026.

What it is worth Healthy

€ 387,038

▼ 24% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -36,000

▲ 88 % less loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 686,197

▲ 32% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -393,223.

People and assets in 2025

Wage cost

€ 475,066

▲ 54% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Debts at end 2025

Bank debt

€ 150,000

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 15,298

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 100,284

▲ 95% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 60,614 Revenue 2022: € 60,614 First fiscal year in the series	€ 60,349 Revenue 2023: € 60,349 Unchanged (€ 60,614) Unfavourable step	€ 6,670 Revenue 2024: € 6,670 ▼ 89% vs 2023 (€ 60,349) Unfavourable step	-
Gross margin	€ 157,284 Gross margin 2022: € 157,284 First fiscal year in the series	€ 191,599 Gross margin 2023: € 191,599 ▲ 22% vs 2022 (€ 157,284) Favourable step	€ 15,258 Gross margin 2024: € 15,258 ▼ 92% vs 2023 (€ 191,599) Unfavourable step	€ 433,649 Gross margin 2025: € 433,649 ▲ € 418,392 vs 2024 (€ 15,258) Favourable step	▲ € 418,392
Profit after taxes	€ -15,192 Profit after taxes 2022: € -15,192 First fiscal year in the series	€ -27,070 Profit after taxes 2023: € -27,070 ▼ € 11,877 vs 2022 (€ -15,192) Unfavourable step	€ -293,396 Profit after taxes 2024: € -293,396 ▼ € 266,327 vs 2023 (€ -27,070) Unfavourable step	€ -36,000 Profit after taxes 2025: € -36,000 ▲ € 257,396 vs 2024 (€ -293,396) Favourable step	▲ € 257,396
Equity	€ 625,736 Equity 2022: € 625,736 First fiscal year in the series	€ 646,401 Equity 2023: € 646,401 ▲ 3% vs 2022 (€ 625,736) Favourable step	€ 510,557 Equity 2024: € 510,557 ▼ 21% vs 2023 (€ 646,401) Unfavourable step	€ 387,038 Equity 2025: € 387,038 ▼ 24% vs 2024 (€ 510,557) Unfavourable step	▼ 24%
Total debts	€ 37,448 Total debts 2022: € 37,448 First fiscal year in the series	€ 38,188 Total debts 2023: € 38,188 ▲ 2% vs 2022 (€ 37,448) Unfavourable step	€ 51,480 Total debts 2024: € 51,480 ▲ 35% vs 2023 (€ 38,188) Unfavourable step	€ 365,582 Total debts 2025: € 365,582 ▲ € 314,102 vs 2024 (€ 51,480) Unfavourable step	▲ € 314,102
Cash	€ 627,299 Cash 2022: € 627,299 First fiscal year in the series	€ 653,353 Cash 2023: € 653,353 ▲ 4% vs 2022 (€ 627,299) Favourable step	€ 520,637 Cash 2024: € 520,637 ▼ 20% vs 2023 (€ 653,353) Unfavourable step	€ 686,197 Cash 2025: € 686,197 ▲ 32% vs 2024 (€ 520,637) Favourable step	▲ 32%
Retained profit	€ -36,758 Retained profit 2022: € -36,758 First fiscal year in the series	€ -63,828 Retained profit 2023: € -63,828 ▼ € 27,070 vs 2022 (€ -36,758) Unfavourable step	€ -357,224 Retained profit 2024: € -357,224 ▼ € 293,396 vs 2023 (€ -63,828) Unfavourable step	€ -393,223 Retained profit 2025: € -393,223 ▼ € 36,000 vs 2024 (€ -357,224) Unfavourable step	▼ € 36,000
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 0 Bank debt 2023: € 0 Unchanged (€ 0) Unchanged	€ 0 Bank debt 2024: € 0 Unchanged (€ 0) Unchanged	€ 150,000 Bank debt 2025: € 150,000 Unchanged (€ 0) Unfavourable step
Balance sheet total	€ 663,184 Balance sheet total 2022: € 663,184 First fiscal year in the series	€ 684,589 Balance sheet total 2023: € 684,589 ▲ 3% vs 2022 (€ 663,184) Unchanged	€ 562,037 Balance sheet total 2024: € 562,037 ▼ 18% vs 2023 (€ 684,589) Unchanged	€ 752,620 Balance sheet total 2025: € 752,620 ▲ 34% vs 2024 (€ 562,037) Unchanged	▲ 34%
Employees (FTE)	3 Employees (FTE) 2022: 3 First fiscal year in the series	3 Employees (FTE) 2023: 3 Unchanged (3) Unchanged	5.3 Employees (FTE) 2024: 5.3 ▲ 2.3 vs 2023 (3) Unchanged	-

Key figures of REVISION IMPLANT, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to REVISION IMPLANT?

What happened at REVISION IMPLANT in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 17, 2026 New annual accounts for financial year 2025: loss of € 36,000. Source: NBB ↗
Dec 23, 2019 New establishment in Oud-Heverlee. KBO
Dec 23, 2019 Start of the company according to the CBE. KBO

In short

From € 15,192 loss in 2022 to € 36,000 loss in 2025.

On average € 2,900 of value added per employee in 2024.

Original PDFs at the National Bank ↗

Management

BOO SERVICES 33.3%

The stake of BOO SERVICES comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

REVISION IMPLANT

Behind REVISION IMPLANT are Jasmine Peeters, Maarten Schelles, Johan Van de Bossche, Dagda Ventures, Frederik Ceyssens and Ruben Verhoeven. The shares are held by BOO SERVICES (33.3%).

Directors

According to the 2025 annual accounts

Jasmine Peeters

Director

Maarten Schelles

Director

Johan Van de Bossche

Director

Dagda Ventures

Director · represented by Erwin De Keyser

Also active at: BELAERO, SAY IT Labs

Frederik Ceyssens

Managing director

Ruben Verhoeven

Director

Also active at: ANDHERS, Dynactionize, Ventures@RV

Shareholders

BOO SERVICES

33.3%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Blandenstraat 31

3053 Oud-Heverlee

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0740.519.675

VAT number

BE 0740.519.675

Registered office

Blandenstraat 31, 3053 Oud-Heverlee

Names & denominations

REVISION IMPLANT

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

23 December 2019

Peppol

Active · Active since 18 Dec 2025

Contact

revision-implant.com [email protected]

Activities · NACE

Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg

Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

Overige gespecialiseerde wetenschappelijke en technische activiteiten

Speur- en ontwikkelingswerk op biotechnologisch gebied

Vervaardiging van bestralingsapparatuur en van elektromedische en elektrotherapeutische apparatuur

Overige dienstverlenende activiteiten op het gebied van informatie

Activiteiten van ingenieurs en aanverwante technische adviseurs, exclusief landmeters-experts

View on CBE Public ↗ Annual accounts (NBB) ↗

REVISION IMPLANT

Warning lights

Financials

What happened to REVISION IMPLANT?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Details

Frequently asked questions